Press Releases

Date Title and Summary
Toggle Summary New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).
Toggle Summary GE Healthcare and Accuray Collaborate to Expand Access, Advance the Practice of Precision Radiation Therapy
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif. , Oct. 21, 2022 /PRNewswire/ -- GE Healthcare and
Toggle Summary Accuray to Report First Quarter Fiscal 2023 Financial Results on November 2, 2022
SUNNYVALE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2023, ended September 30, 2022, after the market close on November 2, 2022. Management will host a conference call to review the results at 1:30
Toggle Summary Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
SUNNYVALE, Calif. , Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (
Toggle Summary Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform
Toggle Summary Accuray to Host Meeting with Analysts and Investors at ASTRO on October 24, 2022
SUNNYVALE, Calif. , Oct. 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a key opinion leader (KOL) discussion with analysts and investors on Monday, October 24, 2022 , in conjunction with the American Society of Radiation Oncology (ASTRO)
Toggle Summary Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients
World's Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out- Patient Sessions SUNNYVALE, Calif. , Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its
Toggle Summary Dr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region
SUNNYVALE, Calif. , Sept. 14, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas ( North and South America ) region. Dr.
Toggle Summary Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster
Accuray Will Anchor Hub That Will Unite Companies From the MedTech , Pharma and Biosciences Sectors, Physicians and Scientists SUNNYVALE, Calif. , Sept. 7, 2022 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub , a
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results
8.5% FY22 revenue growth; Company issues guidance for FY23 SUNNYVALE, Calif. , Aug. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2022 ended June 30, 2022 .     Q4 Fiscal 2022 and Recent Operating Highlights Gross

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.